Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 14, 2015BloodOpen Access

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBruno PaivaNavarre Institute of Health ResearchMMMaría‐Victoria MateosUniversidad Complutense de MadridLSLuis Ignacio Sánchez‐AbarcaUniversidad de Salamanca

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Paiva et al. (2015) studied this question.

synapsesocial.com/papers/6a1708db87c007abbc054e52https://doi.org/10.1182/blood-2015-10-662320
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies2015 · 132 citations
  2. 2The Expression of T Cell Related Costimulatory Molecules in Multiple Myeloma1998 · 70 citations
  3. 3TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function2010 · 150 citations
  4. 4Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance2013 · 136 citations
  5. 5Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)2013 · 197 citations